Logo

Apalutamide Now Also Approved for Metastatic Prostate Cancer

ARTICLES

Apalutamide Now Also Approved for Metastatic Prostate Cancer


MEDSCAPE
PUBLISHED: 19 SEPTEMBER 2019


Last year, apalutamide (Erleada, Janssen) became the first drug to be approved in the United States for use in the treatment of nonmetastatic, castration-resistant prostate cancer. The approval marked the first time that the US Food and Drug Administration used metastasis-free survival as the primary endpoint in its decision making.

explore_now-footer.png

Published

September 19, 2019

Categories

Oncology
CP-202103